Transcept could co-promote Intermezzo after $38m offering
This article was originally published in Scrip
Executive Summary
Transcept Pharmaceuticals' may use some of the $37.6 million offering, priced on 26 April, to allow it to participate in the commercialization of its sleep-aid drug, Intermezzo.